Antibody
Engineering
Engineering and Lead Optimization
Optimize Antibodies for Your Drug Development Pipeline
YUMAB® offers advanced bioinformatics and engineering technologies to improve and optimize existing antibody candidates (also from other sources, e.g. hybridoma). The art of antibody engineering involves a combination of in vitro and AI-assisted in silico technologies to optimize clinically relevant properties.
YuCARE
Placing Priority on Developability, Safety and Efficacy
YUMAB’s YuCARE™ is our integrated AI-driven in silico toolbox for advanced lead candidate selection, antibody engineering, and sequence optimization – designed to generate high-quality candidates for clinical development.
By combining state-of-the-art AI and bioinformatic prediction with rigorous experimental wet-lab validation, we bridge computational design and real-world performance. Instead of testing only individual variants, we design and screen large, highly diverse antibody libraries—ranging from millions to billions of AI-guided sequences—to maximize the probability of identifying optimal candidates.
YuCARE enables the generation of AI-guided CDR mutagenesis libraries for affinity maturation that are simultaneously optimized for developability and rapidly validated within our high-throughput experimental workflow.
In addition, we collaborate with external AI partners by providing advanced wet-lab screening and validation capabilities to accelerate antibody discovery and engineering programs.
